Skip to main content
. 2021 Sep 9;22(18):9751. doi: 10.3390/ijms22189751

Figure 2.

Figure 2

Expression of Smad2 and Smad3 in TGF-β1- exposed pericytes. (A,B) TGF-β1 significantly increased both the p-Smad2 level and the ratio of p-Smad2 to Smad2 in pericytes, and they were decreased after paricalcitol treatment. (A,C) Moreover, TGF-β1 significantly increased both the p-Smad3 level and the ratio of p-Smad3 to Smad3, and they were not altered after paricalcitol treatment. The data are presented as means ± standard errors. n = 4 per each group. * p < 0.05 vs. control; ** p < 0.01 vs. control; *** p < 0.001 vs. control; # p < 0.05 vs. TGF-β1 treatment group. Abbreviations: C, control group; P, paricalcitol treatment group; T, TGF-β1 treatment group; T + P, TGF-β1 and paricalcitol cotreatment group.